- Home
- GDTC
as 11-07-2025 10:09am EST
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
| Founded: | 2018 | Country: | Singapore |
| Employees: | N/A | City: | N/A |
| Market Cap: | 24.8M | IPO Year: | 2023 |
| Target Price: | N/A | AVG Volume (30 days): | 268.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.65 - $4.05 | Next Earning Date: | 01-01-0001 |
| Revenue: | $573,193 | Revenue Growth: | 63.03% |
| Revenue Growth (this year): | 5.37% | Revenue Growth (next year): | N/A |
Latest CytoMed Therapeutics Limited News
GDTC Breaking Stock News: Dive into GDTC Ticker-Specific Updates for Smart Investing
GlobeNewswire
16 days ago
CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%
GlobeNewswire
24 days ago
CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets
MT Newswires
5 months ago
CytoMed Therapeutics Files $50 Million Mixed Shelf
Simply Wall St.
6 months ago
CytoMed Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
GlobeNewswire
6 months ago
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
GlobeNewswire
9 months ago
CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders
Simply Wall St.
9 months ago
Anebulo Pharmaceuticals Leads This Trio Of US Penny Stocks
TipRanks
10 months ago
CytoMed and SunAct Collaborate on Cancer Immunotherapy Trials in India
Compare GDTC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GDTC CytoMed Therapeutics Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.